Dual-functionalized graphene oxide for enhanced siRNA delivery to breast cancer cells (2016)
Sequence: RRRRRRRR
| Experiment Id | EXP001601 |
|---|---|
| Paper | Dual-functionalized graphene oxide for enhanced siRNA delivery to breast cancer cells |
| Peptide | R8 (octaarginine) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | R8 added at 1 mM during nano-carrier functionalization (preparation step) |
| Rna Concentration | 75 ng cd-siRNA per well (cell death assay); 100 ng FITC-siRNA (uptake/localization assays) |
| Mixing Ratio | N/P = 10 (optimal; complete gel retardation) |
| Formulation Format | non-covalent dual-functionalized rGO nano-carrier complexed with siRNA |
| Formulation Components | rGON-PLPEG-R8 (reduced graphene oxide + PL-PEG amphiphilic polymer + R8 peptide) / siRNA complexes |
| Size Nm | 247.00 |
| Zeta Mv | 42.60 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | MCF-7 breast cancer cells |
| Animal Model | |
| Administration Route | |
| Output Type | cell death / viability (MTS) after cd-siRNA delivery |
| Output Value | ~51 ± 3.1% cell viability vs non-treated (72 h post-transfection) |
| Output Units | |
| Output Notes | R8-coated rGON-PLPEG delivered siRNA with ~82 ± 5.1% internalization efficacy vs HiPerFect (FITC-siRNA assay); confocal showed decreased co-localization with lysosomes over time, consistent with endosomal escape. |
| Toxicity Notes | Nano-carrier alone: viability remained >85% up to 200 µg/mL; HiPerFect reduced viability even without cd-siRNA. |
| Curation Notes |